SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users share the project's website, Telegram, and X (formerly Twitter) community links, touting it as 'like Bitcoin but way higher'. The community emphasizes the coin's culture, positivity, and innovation, while highlighting its roots on the Solana blockchain.

Exodus Movement, Inc. develops blockchain asset investors platform to secure, exchange and manage wealth inside one application. The company was founded by Daniel Castagnoli and Jon Paul Richardson in 2015 and is headquartered in Omaha, NE.

Exodus Movement Inc - Ordinary Shares - Class A

EXOD is trending as investors discuss its potential as a leading crypto payment company and Web3 ecosystem. Community members are highlighting the company's recent acquisition and loan from $GLXY, speculating on future strategic moves and revenue growth. Bullish sentiment revolves around the belief that EXOD is ahead of the curve in crypto-finance and is undervalued given its assets and revenue potential.

CME Group, Inc. operates a derivatives marketplace, which offers a range of futures and options products for risk management. Its exchanges offer a range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange (FX), energy, agricultural commodities and metals. It offers futures and options on futures trading across asset classes through the CME Globex platform, fixed income trading via BrokerTec and FX trading on the EBS platform. In addition, it also operates CME Clearing, a central counterparty clearing provider. The company was founded in 1898 and is headquartered in Chicago, IL.

CME Group Inc - Ordinary Shares - Class A

CME Group Inc

CME Group is trending due to a cooling system failure that halted global derivatives trading, raising concerns about financial infrastructure vulnerabilities; the community is discussing the outage's impact and potential setups in the stock. Despite the downtime, CME is seen as a 'taxes every volatility spike' powerhouse, with analysts actively weighing in on its prospects amid broader market trends and crypto developments.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing ($BA) is trending due to an urgent Airbus recall affecting thousands of A320 aircraft, potentially shifting business to Boeing. The community is discussing whether this is a bullish catalyst for BA, while others are focused on recent defense contracts. Some believe the stock is undervalued, while others cite ongoing production issues and certification delays as concerns.

The PNC Financial Services Group, Inc. is a holding company, which engages in the provision of financial services. It operates through the following segments: Retail Banking, Corporate and Institutional Banking, Asset Management Group, and Other. The Retail Banking segment offers deposit, lending, brokerage, investment management, and cash management products and services to consumer and small business customers. The Corporate and Institutional segment covers the lending, treasury management, and capital markets-related products and services to mid-sized and large corporations, government, and not-for-profit entities. The Asset Management Group segment includes personal wealth management for high net worth and ultra-high net worth clients and institutional asset management. The company was founded in 1983 and is headquartered in Pittsburgh, PA.

PNC Financial Services Group Inc

PNC Financial Services Group

PNC is trending due to a mix of factors, including analysts adjusting their ratings and price targets, and discussions around the bank's expansion strategy with new branches. Community discussions also involve dividend payouts and speculation about potential acquisitions. Recent news highlights PNC's focus on community development and technology initiatives, influencing investor sentiment.

Realty Income Corp. is a real estate company, which engages in generating dependable monthly cash dividends from a consistent and predictable level of cash flow from operations. The company was founded by William E. Clark, Jr. and Evelyn Joan Clark in 1969 and is headquartered in San Diego, CA.

Realty Income Corp.

Realty Income is trending as investors discuss its dividend yield and the potential impact of interest rate cuts on REITs. Community members are debating whether to buy, hold, or sell, with some highlighting its expansion into Europe and others expressing concerns about its growth prospects. There's also discussion around its valuation compared to peers and whether it's a good long-term investment, emphasizing its stability and monthly dividend payouts.

BlackRock Institutional Trust Company N.A. - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF ($FXI) is trending amid discussions around US-China trade relations and potential impacts from tariffs. Community chatter highlights mixed signals, with some anticipating a policy shift and others fearing further escalation of trade tensions. Investors are closely monitoring economic data and policy announcements for directional cues.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the Commercial Engines & Services and Defense & Propulsion Technologies segments. The Commercial Engines & Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense & Propulsion Technologies segment offers defense engines and critical aircraft systems. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospace is trending as investors digest its recent earnings beat, raised outlook, and potential for long-term growth in the aviation sector. Community discussions revolve around the company's strategic partnerships, defense contracts, and the possibility of reaching new all-time highs, with some also weighing the impact of a potential economic correction. Additionally, investors are monitoring a settlement payout related to past financial reporting.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending as investors discuss its recent price pullback despite seemingly strong fundamentals and a history of positive earnings. Community members are debating potential catalysts, including a possible acquisition, positive news, or increased institutional investment, to drive the stock back up. Some are expressing frustration with the stock's performance and management's silence, while others remain confident in its long-term potential, citing a share buyback program and future revenue projections.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending amid discussions about its faster growth and cheaper valuation compared to competitors like Sea Limited, with some analysts highlighting its expanding AI ecosystem. Community members are debating the stock's recent performance despite it being the busiest time of the year for e-commerce, while others are focused on options activity and potential upside. There's also some discussion about potential challenges, including rising competition and concerns around its operations in Uruguay.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Avalo Therapeutics (NASDAQ:AVTX) Posts Quarterly Earnings Results, Misses Estimates By $0.52 EPS

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts...

<ul class="summary-bullets"><li>Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.</li><li>Analysts at H.C. Wainwright, Oppenheimer, TD Cowen, and Cantor Fitzgerald maintain bullish views on Avalo, with price targets ranging from $25 to $35 and expectations that AVTX-009 could outperform AbbVie’s rival therapy.</li><li>On Stocktwits, sentiment turned ‘extremely bullish’ as message activity surged; users highlighted fresh opportunities and long-term upside.</li></ul>Shares of Avalo Therapeutics gained 0.4% in premarket trading on Wednesday amid upbeat investor sentiment ahead of an Oppenheimer analyst call focused on its lead drug candidate, AVTX-009, for hidradenitis suppurativa.&nbsp;The stock is currently trading at a nearly 18-month high.&nbsp;<h2 class="st-heading-2">Pipeline And Trial Progress</h2>Earlier this month, Avalo said it had dosed the first patient in the LOTUS study. The randomized, double-blind, placebo-controlled trial is testing two dosing regimens of AVTX-009, with top-line results expected in 2026.The study’s primary endpoint is the proportion of patients achieving HiSCR75, a 75% reduction in abscess and nodule count at week 16, while secondary measures include HiSCR50 and HiSCR90 response rates, improvements in skin pain and lesion severity, and safety outcomes.AVTX-009 targets interleukin-1β, a cytokine involved in the inflammatory cascade driving HS and several other autoimmune diseases. The drug’s mechanism builds on clinical validation seen with other IL-1 inhibitors and aims to deliver higher potency and longer durability.<h2 class="st-heading-2">Analyst Views&nbsp;</h2>Avalo has drawn attention from multiple brokerages since restarting its HS program this year.In September, H.C. Wainwright raised its price target on Avalo Therapeutics to $25 from $15 and reiterated a ‘Buy’ rating, saying AbbVie’s latest hidradenitis suppurativa data validated the IL-1 pathway but capped efficacy at 45%–50% HiSCR75.Earlier that month, Oppenheimer recommended investors be buyers of Avalo shares ahead of lutikizumab’s open-label Phase 2 data, forecasting “strong results” and expecting AVTX-009, with multiple advantages over lutikizumab, to deliver “at least as good as, and potentially better, efficacy” when LOTUS trial results&nbsp;are read out in mid-2026. The firm maintained an ‘Outperform’ rating and a $35 price target.Separately, TD Cowen initiated coverage with a ‘Buy’ rating, citing AVTX-009’s Phase 2 study in hidradenitis suppurativa and highlighting the high unmet need in a heterogeneous patient population, estimating over $1 billion sales potential.&nbsp;Cantor Fitzgerald also began coverage with an ‘Overweight’ rating, describing Avalo as a clinical-stage biotech focused on autoimmune diseases and noting that AVTX-009, an IL-1N2 antibody, is expected to have a mid-2026 readout.<h2 class="st-heading-2">Stocktwits Traders See Long-Term Upside</h2>On Stocktwits, retail sentiment for Avalo was ‘extremely bullish’ amid a 20% surge in 24-hour message volume.One user noted that the setup still offered opportunities and encouraged others to stay tuned.<stembedurl>https://stocktwits.com/topstockalerts/message/632967338</stembedurl>Another user suggested that Avalo looked like a strong buy and could deliver twentyfold returns for investors willing to hold long term.<stembedurl>https://stocktwits.com/WallGoodman/message/632883343</stembedurl><a href="https://stocktwits.com/symbol/AVTX">Avalo’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avalo’s stock has more than doubled so far in 2025. (Photo credit: Getty Images)

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug

Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.

Equity

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of...

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 29/03/2024

Gagnants
Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market.
Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...

12 titoli sanitari in movimento, pre-market del 29/03/2024

Titoli in rialzo
Le azioni di Avalo Therapeutics (NASDAQ:AVTX) sono cresciute del 289,05% a 18,48 dollari durante la sessione pre-market di venerd .
Il titolo Xilio Therapeutics (NASDAQ:XLO) salito...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

$AMZN

$MSFT

$GOOGL

$ORCL

Which cloud infrastructure stock offers the best long-term opportunity right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.52	--	--	N/A
Q3 '25	-$1.66	-$2.19	-32.06%	MISSED
Q2 '25	-$1.40	-$1.92	-36.92%	MISSED
Q1 '25	-$1.18	-$1.25	-5.78%	MISSED
Q4 '24	-$0.17	--	--	N/A

AVTX
Avalo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest AVTX News

AVTXAvalo Therapeutics Inc